Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598793 · ClinicalTrials.gov registry record · Phase 3
Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
NCT00598793 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 242 participants.
The verdict
NCT00598793, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to compare biphasic insulin aspart 30 plus metformin in a standard injection regimen to a standard dosing of insulin glargine plus metformin on blood glucose control in subjects with type 2 diabetes who are insulin naive and failing OAD therapy.
Interventions
- DRUG metformin
- DRUG biphasic insulin aspart
- DRUG insulin glargine
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00598793
The ClinicalTrials.gov registry entry for NCT00598793 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which metformin is the first listed.
NCT00598793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00598793 about?
NCT00598793 is a clinical study titled "Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy". This trial is conducted in the United States of America (USA). The aim of this trial is to compare biphasic insulin aspart 30 plus metformin in a standard injection regimen to a standard dosing of insulin glargine plus metformin on blood glucose control in subjects with type 2 diabetes who are insul...
What is the current status of trial NCT00598793?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2002-11. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00598793?
The interventions under investigation include: metformin (DRUG), biphasic insulin aspart (DRUG), insulin glargine (DRUG), pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00598793?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.